Tyra Biosciences, Inc. TYRA
We take great care to ensure that the data presented and summarized in this overview for Tyra Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TYRA
View all-
Ra Capital Management, L.P. Boston, MA10.4MShares$160 Million3.41% of portfolio
-
Boxer Capital, LLC San Diego, CA6.45MShares$99 Million8.05% of portfolio
-
Bvf Inc San Francisco, CA4.66MShares$71.6 Million3.48% of portfolio
-
Canaan Partners Xi LLC Menlo Park, CA4.41MShares$67.7 Million97.89% of portfolio
-
Nextech Invest Ag4.06MShares$62.3 Million15.55% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.99MShares$30.6 Million6.07% of portfolio
-
Black Rock Inc. New York, NY1.42MShares$21.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.25MShares$19.1 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X01.07MShares$16.4 Million0.01% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA939KShares$14.4 Million8.8% of portfolio
Latest Institutional Activity in TYRA
Top Purchases
Top Sells
About TYRA
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Insider Transactions at TYRA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 08
2024
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,220,681
+12.31%
|
$19,530,896
$16.25 P/Share
|
|
Nov 07
2024
|
Nina S Kjellson |
SELL
Open market or private sale
|
Indirect |
22,091
-0.53%
|
$375,547
$17.32 P/Share
|
|
Nov 06
2024
|
Nina S Kjellson |
SELL
Open market or private sale
|
Indirect |
52,491
-1.23%
|
$892,347
$17.18 P/Share
|
|
Nov 05
2024
|
Nina S Kjellson |
SELL
Open market or private sale
|
Indirect |
10,493
-0.25%
|
$167,888
$16.77 P/Share
|
|
Nov 04
2024
|
Nina S Kjellson |
SELL
Open market or private sale
|
Indirect |
1,076
-0.03%
|
$18,292
$17.01 P/Share
|
|
Nov 01
2024
|
Nina S Kjellson |
SELL
Open market or private sale
|
Indirect |
26,889
-0.42%
|
$430,224
$16.75 P/Share
|
|
Nov 01
2024
|
Nina S Kjellson |
SELL
Open market or private sale
|
Indirect |
604
-0.02%
|
$10,268
$17.16 P/Share
|
|
Oct 31
2024
|
Nina S Kjellson |
SELL
Open market or private sale
|
Indirect |
100,140
-2.28%
|
$1,602,240
$16.46 P/Share
|
|
Oct 30
2024
|
Nina S Kjellson |
SELL
Open market or private sale
|
Indirect |
11,078
-0.25%
|
$177,248
$16.17 P/Share
|
|
Oct 30
2024
|
Alan Fuhrman Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
9,500
+42.51%
|
$152,000
$16.0 P/Share
|
|
Oct 21
2024
|
Todd Harris President and CEO |
SELL
Open market or private sale
|
Direct |
19,084
-0.7%
|
$515,268
$27.74 P/Share
|
|
Oct 18
2024
|
Boxer Capital Management, LLC |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
2,000,000
-31.02%
|
-
|
|
Oct 18
2024
|
Todd Harris President and CEO |
SELL
Open market or private sale
|
Direct |
43,636
-3.08%
|
$1,178,172
$27.01 P/Share
|
|
Oct 18
2024
|
Ra Capital Management, L.P. |
SELL
Other acquisition or disposition
|
Indirect |
1,000,000
-11.8%
|
-
|
|
Oct 17
2024
|
Todd Harris President and CEO |
SELL
Open market or private sale
|
Direct |
15,394
-0.54%
|
$400,244
$26.11 P/Share
|
|
Oct 16
2024
|
Todd Harris President and CEO |
SELL
Open market or private sale
|
Direct |
33,297
-0.76%
|
$865,722
$26.14 P/Share
|
|
Oct 15
2024
|
Todd Harris President and CEO |
SELL
Open market or private sale
|
Direct |
10,035
-0.68%
|
$240,840
$24.31 P/Share
|
|
Sep 30
2024
|
Todd Harris President and CEO |
SELL
Open market or private sale
|
Direct |
500
-0.03%
|
$12,000
$24.0 P/Share
|
|
Sep 25
2024
|
Todd Harris President and CEO |
SELL
Open market or private sale
|
Direct |
600
-0.04%
|
$14,400
$24.01 P/Share
|
|
Sep 24
2024
|
Todd Harris President and CEO |
SELL
Open market or private sale
|
Direct |
1,055
-0.07%
|
$25,320
$24.02 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 3.25M shares |
|---|---|
| Open market or private purchase | 1.23M shares |
| Exercise of conversion of derivative security | 86.8K shares |
| Other acquisition or disposition | 1M shares |
|---|---|
| Open market or private sale | 600K shares |
| Sale (or disposition) back to the issuer | 2M shares |